Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

PLx Pharma Inc (PLXP) USD0.001

Sell:$17.75 Buy:$17.80 Change: $0.77 (4.52%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.77 (4.52%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.77 (4.52%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PLx Pharma Inc. is a pharmaceutical company. The Company is focused on its PLxGuard drug delivery platform. Its core product includes VAZALORE, available in two doses 325miligram (mg) and 81 mg, is a formulation of aspirin clinically shown to provide platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy. Its PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the GI tract. Its product pipeline also includes other oral non-steroidal anti-inflammatory drugs (NSAIDs) using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage.

Contact details

9 Fishers Ln Ste E
United States
+1 (713) 8421249

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$457.94 million
Shares in issue:
26.89 million
United States
US dollar

Key personnel

  • Rita O Connor
    Chief Financial Officer
  • Robert Shawah
    Chief Accounting Officer, Treasurer
  • Steven Valentino
    Vice President - Trade Sales
  • Tom Long
    Vice President - Manufacturing & Technical Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.